{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:08:45Z","timestamp":1791065325585,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015311","name":"Novartis Institutes for BioMedical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jocn.2023.11.013","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T14:11:21Z","timestamp":1700489481000},"page":"76-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study"],"prefix":"10.1016","volume":"119","author":[{"given":"Baltazar","family":"GomezMancilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew N.","family":"Meriggioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Genge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronenn","family":"Roubenoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Espi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Pezous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Kinhikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Tichy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Dionne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vissing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farida","family":"Devlikamova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Poverennova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Stuchevskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thy-Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gergely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2023.11.013_b0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nmd.2015.10.009","article-title":"Epidemiology of myasthenia gravis in Ontario, Canada","volume":"26","author":"Breiner","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jocn.2023.11.013_b0010","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2023.11.013_b0015","article-title":"Myasthenia gravis: a review","volume":"2012","author":"Jayam Trouth","year":"2012","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.jocn.2023.11.013_b0020","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11940-014-0283-8","article-title":"Treatment of MuSK-associated myasthenia gravis","volume":"16","author":"El-Salem","year":"2014","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.jocn.2023.11.013_b0025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1468-1331.2005.01137.x","article-title":"Seronegative myasthenia gravis: disease severity and prognosis","volume":"12","author":"Romi","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2023.11.013_b0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s13311-015-0398-y","article-title":"Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis","volume":"13","author":"Guptill","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jocn.2023.11.013_b0035","doi-asserted-by":"crossref","first-page":"7868","DOI":"10.4049\/jimmunol.177.11.7868","article-title":"Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia","volume":"177","author":"Le Panse","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jocn.2023.11.013_b0040","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1111\/ajt.14872","article-title":"Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody","volume":"18","author":"Ristov","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jocn.2023.11.013_b0045","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ajt.15661","article-title":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","volume":"20","author":"Espie","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jocn.2023.11.013_b0050","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz013","article-title":"A Novel anti-CD40 monoclonal antibody, iscalimab, for control of graves hyperthyroidism-A proof-of-concept trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocn.2023.11.013_b0055","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjogren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jocn.2023.11.013_b0060","doi-asserted-by":"crossref","unstructured":"Jaretzki A, 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55:16-23.","DOI":"10.1212\/WNL.55.1.16"},{"key":"10.1016\/j.jocn.2023.11.013_b0065","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jocn.2023.11.013_b0070","doi-asserted-by":"crossref","unstructured":"Muppidi S, Wolfe GI, Conaway M, Burns TM, Mg C, Mg-Qol15 Study G. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44:727-31.","DOI":"10.1002\/mus.22140"},{"key":"10.1016\/j.jocn.2023.11.013_b0075","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.21883","article-title":"The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis","volume":"43","author":"Burns","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2023.11.013_b0080","doi-asserted-by":"crossref","unstructured":"Burns TM, Conaway M, Sanders DB, Composite MG, Group M-QS. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74:1434-40.","DOI":"10.1212\/WNL.0b013e3181dc1b1e"},{"key":"10.1016\/j.jocn.2023.11.013_b0085","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2023.11.013_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2005.12.041","article-title":"Target-mediated drug disposition and dynamics","volume":"72","author":"Mager","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jocn.2023.11.013_b0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11095-005-8814-3","article-title":"Pharmacokinetics\/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers","volume":"23","author":"Ng","year":"2006","journal-title":"Pharm Res"},{"key":"10.1016\/j.jocn.2023.11.013_b0100","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/ajt.13377","article-title":"A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion","volume":"15","author":"Cordoba","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jocn.2023.11.013_b0105","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2016-eular.3467","article-title":"Assessment of safety, pharmacokinetics and pharmacodynamics of a novel anti-Cd40 monoclonal antibody, Cfz533, in healthy volunteers and in rheumatoid arthritis patients","volume":"75","author":"Slade","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jocn.2023.11.013_b0110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/CND.0b013e31824619d5","article-title":"The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers","volume":"13","author":"Barnett","year":"2012","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.jocn.2023.11.013_b0115","first-page":"192","article-title":"Nonclinical safety assessment of CFZ533, a Fc-silent anti-CD40 antibody, in cynomolgus monkeys","volume":"166","author":"Ulrich","year":"2018","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jocn.2023.11.013_b0120","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5582\/irdr.2019.01121","article-title":"Quality of life in refractory generalized myasthenia gravis: A rapid review of the literature","volume":"8","author":"Garzon-Orjuela","year":"2019","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.jocn.2023.11.013_b0125","doi-asserted-by":"crossref","unstructured":"Mullins LL, Carpentier MY, Paul RH, Sanders DB, Muscle Study G. Disease-specific measure of quality of life for myasthenia gravis. Muscle Nerve. 2008;38:947-56.","DOI":"10.1002\/mus.21016"},{"issue":"Suppl 112","key":"10.1016\/j.jocn.2023.11.013_b0130","first-page":"3","article-title":"Highlights of the 14th International Symposium in Sjogren's Syndrome","volume":"36","author":"Bombardieri","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jocn.2023.11.013_b0135","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1073\/pnas.1520112113","article-title":"CXCL13 is a plasma biomarker of germinal center activity","volume":"113","author":"Havenar-Daughton","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jocn.2023.11.013_b0140","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4049\/jimmunol.1500725","article-title":"Augmentation of circulating follicular helper T cells and their impact on autoreactive B cells in myasthenia gravis","volume":"197","author":"Zhang","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.jocn.2023.11.013_b0145","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nature07345","article-title":"SAP-controlled T-B cell interactions underlie germinal centre formation","volume":"455","author":"Qi","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jocn.2023.11.013_b0150","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2005.09.001","article-title":"Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients","volume":"170","author":"Saito","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2023.11.013_b0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13023-018-0837-z","article-title":"Thymectomy in nonthymomatous myasthenia gravis - systematic review and meta-analysis","volume":"13","author":"Cataneo","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jocn.2023.11.013_b0160","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jtcvs.2011.04.050","article-title":"Active ectopic thymus predicts poor outcome after thymectomy in class III myasthenia gravis","volume":"143","author":"Ambrogi","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jocn.2023.11.013_b0165","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.autrev.2013.03.011","article-title":"Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis","volume":"12","author":"Berrih-Aknin","year":"2013","journal-title":"Autoimmun Rev"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586823003430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586823003430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:34:29Z","timestamp":1760823269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586823003430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":33,"alternative-id":["S0967586823003430"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2023.11.013","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2023.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}